In a phase 3 trial of 461 patients with untreated unresectable oesophageal squamous cell carcinoma, tiragolumab plus atezolizumab and chemotherapy improved median PFS (6.2 vs 5.4 months; HR 0.56) and OS (15.7 vs 11.1 months; HR 0.70) vs placebo and chemotherapy.
RCTn = 461
Hsu et al. Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial